Kymera Therapeutics 3Q 2026: Revenue $0 Net loss $132M, EPS $(1.32) — 10-Q Summary
Kymera Therapeutics reported 3Q 2026 revenue of $0, down from $2.8M a year earlier, and a net loss of $132M, or $(1.32) per share, compared to a net loss of $82.2M, or $(0.94) per share, in the prior-year quarter. The company's collaboration revenue for the nine months increased to $99.4M, driven by partnerships with Gilead and Sanofi. Research and development spending rose 49%, primarily due to expanded program work and personnel investments.
How this was made
The 30-second read
Why it matters
The earnings miss and lack of revenue are likely to depress the stock, though upcoming trial data could provide a catalyst.
Market read
Earnings release provides fresh data for a micro‑cap biotech, likely prompting immediate price action.
What to watch
Potential future collaboration revenue from Sanofi and Gilead could offset current losses if milestones are met.
Background
Kymera Therapeutics filed its Q3 2026 10‑Q, reporting zero revenue and a $132M net loss, with updates on its clinical pipeline and collaborations.
Ticker impact
Q3 2026 revenue of $0 and net loss of $132M were disclosed in the 10‑Q filing.
downward pressure as investors price in the expanded loss and lack of revenue
Earnings release shows no revenue and a $50M increase in net loss versus prior year, which typically triggers sell‑offs in micro‑cap biotech stocks.
Market effects
Highlights continued cash‑burn in early‑stage biotech sector, may pressure peer valuations.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
If the upcoming Phase 2b data for KT‑621 shows strong efficacy, the loss may be viewed as a temporary investment in pipeline value.
Key entities
- companyKymera Therapeutics
Biotech firm developing targeted protein degradation therapies.
- partnerSanofi
Pharma partner that dosed first participant in a Phase 1 trial.
- partnerGilead
Licensed KT‑200 for global development.
